TNXP earnings analysis
What we found in TNXP's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Tonix delivered a strong commercial quarter, with revenue of $13.544 million, TONMYA revenue of $10.954 million, and diluted EPS of $(2.44), both ahead of consensus. Gross margin rebounded to approximately 94.8%, but operating losses widened as R&D and SG&A increased substantially to support pipeline development and commercialization. Liquidity remains the key constraint: operating cash burn was $84.561 million in the first half, management expects funding only into early Q2 2027, and the filing includes substantial doubt about the company’s ability to continue as a going concern. The company stated that there were no material changes to the risk factors from its December 31, 2025 Form 10-K.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue beat driven by TONMYA
- Second-quarter revenue increased to $13.544 million from $1.998 million year over year and exceeded the $7.832 million consensus estimate. TONMYA contributed $10.954 million versus $0 in the prior-year quarter.
- Gross margin rebounded sharply
- Gross margin was approximately 94.8%, up from negative 63.8% in Q2 2025 and 77.1% in Q1 2026. Cost of sales fell to $0.703 million from $3.272 million, partly because Q2 2025 included approximately $2.3 million of inventory write-downs.
- EPS beat despite higher net loss
- Diluted EPS improved to $(2.44) from $(3.86) year over year and beat the $(2.64) consensus estimate. Net loss was $(40.552) million versus $(28.272) million in Q2 2025, reflecting substantially higher commercial and development spending.
- All commercial products grew
- TONMYA revenue reached $10.954 million, while Zembrace SymTouch revenue grew to $1.996 million from $1.570 million. Tosymra revenue increased to $0.594 million from $0.428 million.
- Pipeline investment accelerated
- Research and development expense increased 80% to $19.417 million from $10.820 million, driven by $4.5 million of higher manufacturing expense, $1.3 million of higher clinical expense, and $2.5 million of higher employee-related costs.
- Pipeline milestones advanced
- The company received positive final FDA Type C meeting minutes for TNX-4800 in early Q3 2026, supporting a planned adaptive Phase 2 field study in Q1 2027. The HORIZON Phase 2 study of TNX-102 SL in major depressive disorder commenced in June 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Going-concern and financing risk
- Operating cash flow was negative $84.561 million in the first six months, compared with negative $31.412 million in the prior-year period. Management states cash resources and $3.7 million of post-quarter equity proceeds fund operations only into early Q2 2027 and do not cover 12 months from filing.
- Operating expenses remain elevated
- Selling, general and administrative expense rose 122% to $35.959 million from $16.202 million, including a $13.8 million increase in sales and marketing expense. Research and development expense also rose 80% to $19.417 million, keeping the operating loss at $(42.535) million.
- Pipeline commitments and dilution
- The company had $53.3 million of outstanding commitments to contract research organizations at June 30, 2026, while accumulated deficit reached $935.5 million. Management states additional funding may require equity or debt issuance, which could cause further shareholder dilution or require program reductions.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-2.44
- Gross margin
- 94.8%
- Operating margin
- -314.1%
- Segment
- Single reportable segment: total product revenue was $13.544 million, including TONMYA $10.954 million, Zembrace SymTouch $1.996 million, and Tosymra $0.594 million.
What they said about what is next.
No numeric revenue or EPS guidance was provided. Management expects cash resources at June 30, 2026 plus $3.7 million of subsequent equity proceeds to fund operations and capital expenditures into early Q2 2027, but states resources will not cover 12 months from the filing date. TNX-4800 Phase 2 initiation is planned for Q1 2027, TNX-1500 Phase 2 is expected in the second half of 2026 pending FDA clearance, and OASIS topline data is expected in mid-2027.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 11, 2026
- Tonix Pharmaceuticals reported a significant increase in revenue for Q1 2026, generating $6.9 million, primarily from the sales of its newly launched product TONMYA and existing products Zembrace and Tosymra. However,…
- 10-K · March 12, 2026
- Tonix converted to a commercial-stage biotech in 2025 with FDA approval and a November 17, 2025 launch of TONMYA for fibromyalgia and continued promotion of its migraine franchise. The company shows early commercial…
- 10-Q · November 10, 2025
- Tonix reported Q3 product revenue of $3.29M (up from $2.822M in Q3 2024) and a net loss of $32.01M (operating loss $33.07M), driven by a large rise in SG&A ahead of the Tonmya commercial launch. Cash and cash…
- 10-K · March 18, 2025
- Tonix filed an NDA for TNX-102 SL in October 2024 and the FDA assigned a PDUFA goal date of August 15, 2025; the company is preparing for a potential commercial launch in Q4 2025 conditional on approval. The company…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing TNXP makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever